These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20875492)

  • 1. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.
    Lahey T; Arbeit RD; Bakari M; Horsburgh CR; Matee M; Waddell R; Mtei L; Vuola JM; Pallangyo K; von Reyn CF
    Vaccine; 2010 Nov; 28(48):7652-8. PubMed ID: 20875492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.
    Vuola JM; Ristola MA; Cole B; Järviluoma A; Tvaroha S; Rönkkö T; Rautio O; Arbeit RD; von Reyn CF
    AIDS; 2003 Nov; 17(16):2351-5. PubMed ID: 14571187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.
    Lahey T; Matee M; Mtei L; Bakari M; Pallangyo K; von Reyn CF
    BMC Infect Dis; 2009 Feb; 9():21. PubMed ID: 19236695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.
    Lahey T; Sheth S; Matee M; Arbeit R; Horsburgh CR; Mtei L; Mackenzie T; Bakari M; Vuola JM; Pallangyo K; von Reyn CF
    J Infect Dis; 2010 Oct; 202(8):1265-72. PubMed ID: 20812851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial.
    Matee M; Lahey T; Vuola JM; Mtei L; Cole BF; Bakari M; Arbeit RD; Horsburgh CR; Pallangyo K; von Reyn CF
    J Infect Dis; 2007 Jan; 195(1):118-23. PubMed ID: 17152015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
    von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
    PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis.
    Lahey T; Czechura T; Crabtree S; Arbeit RD; Matee M; Horsburgh CR; MacKenzie T; Bakari M; Pallangyo K; von Reyn CF
    J Infect Dis; 2013 Nov; 208(10):1629-33. PubMed ID: 23908490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
    Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
    PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunoprophylaxis of recombinant Mycobacterium vaccae secreted MPT64 of Mycobacterium tuberculosis].
    Bai YL; Xue Y; Wang LM; Fan AL; Zhang W; Kang J; He JJ; Xu ZK
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Mar; 25(3):211-4. PubMed ID: 19257983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.
    Lahey T; Laddy D; Hill K; Schaeffer J; Hogg A; Keeble J; Dagg B; Ho MM; Arbeit RD; von Reyn CF
    PLoS One; 2016; 11(12):e0168521. PubMed ID: 27997597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.
    von Reyn CF; Mtei L; Arbeit RD; Waddell R; Cole B; Mackenzie T; Matee M; Bakari M; Tvaroha S; Adams LV; Horsburgh CR; Pallangyo K;
    AIDS; 2010 Mar; 24(5):675-85. PubMed ID: 20118767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area.
    Jiang W; Shao L; Zhang Y; Zhang S; Meng C; Xu Y; Huang L; Wang Y; Wang Y; Weng X; Zhang W
    BMC Immunol; 2009 May; 10():31. PubMed ID: 19476627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization.
    Lahey T; Mitchell BK; Arbeit RD; Sheth S; Matee M; Horsburgh CR; MacKenzie T; Mtei L; Bakari M; Vuola JM; Pallangyo K; von Reyn CF
    PLoS One; 2011; 6(7):e22074. PubMed ID: 21799772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice.
    Zhang H; Peng P; Miao S; Zhao Y; Mao F; Wang L; Bai Y; Xu Z; Wei S; Shi C
    Scand J Immunol; 2010 Oct; 72(4):349-57. PubMed ID: 20883320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
    Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
    AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.